| Rank | Stock | Price | Rev. Gr. | Dist. 52WH | Perf. 20D |
|---|---|---|---|---|---|
| WKN | Symbol | EPS Growth | Rel. Strength | |||
| 1 | Verisk Analytics | 278.09 $ | 26.37 % | 9.32 % | -3.45 % |
| A0YA2M | VRSK | 88.86 % | 86 | |||
| 2 | Palomar Holdings | 130.13 $ | 40.22 % | 9.49 % | -0.24 % |
| A2PHB6 | PLMR | 49.48 % | 96 | |||
| 3 | HCI Group | 137.14 $ | 49.16 % | 9.70 % | -1.56 % |
| A1W02H | HCI | 199.39 % | 85 | |||
| 4 | Progressive | 259.68 $ | 22.67 % | 11.37 % | -6.44 % |
| 865496 | PGR | 198.70 % | 88 | |||
| 5 | Universal Technical Institute | 26.47 $ | 20.63 % | 13.39 % | -1.64 % |
| 590097 | UTI | 533.33 % | 96 | |||
| 6 | Halozyme Therapeutics | 56.53 $ | 21.35 % | 14.34 % | -7.15 % |
| A0DLHS | HALO | 60.73 % | 92 | |||
| 7 | Insulet | 246.49 $ | 27.42 % | 14.84 % | -0.76 % |
| A0MQX8 | PODD | 250.00 % | 92 | |||
| 8 | Interdigital | 192.19 $ | 28.53 % | 17.15 % | -9.55 % |
| A0MWY3 | IDCC | 41.33 % | 98 | |||
| 9 | Tradeweb Markets | 122.34 $ | 29.44 % | 19.86 % | -8.22 % |
| TW | 20.69 % | 84 | |||
| 10 | Catalyst Pharmaceuticals | 20.86 $ | 32.17 % | 20.27 % | -1.62 % |
| A0LCUL | CPRX | 111.86 % | 90 |
| Halozyme Therapeutics | |
|---|---|
| 5-year chart | |
| Mkt. cap. | 8.40 B USD |
| P/S 24 | 8.71 |
| P/S 25 | 6.69 |
| P/E 24 | 20.93 |
| P/E 25 | 11.75 |
Business Drivers: The US biotech company Halozyme Therapeutics (HALO) specializes in products related to proprietary enzyme technology. The ENHANZE technology developed by Halozyme allows for the subcutaneous administration of biological and medicinal substances, which offers significant advantages...
